• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".

作者信息

Cattrini Carlo, Messina Carlo, Mennitto Alessia, Di Maio Massimo, Gennari Alessandra, Olmos David

机构信息

Medical Oncology-Department of Translational Medicine (DIMET), Università del Piemonte Orientale (UPO), "Maggiore della Carità" University Hospital, Novara, Italy.

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa, Italy.

出版信息

Int J Cancer. 2022 Dec 15;151(12):2291-2292. doi: 10.1002/ijc.34246. Epub 2022 Sep 5.

DOI:10.1002/ijc.34246
PMID:35975447
Abstract
摘要

相似文献

1
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".关于“醋酸阿比特龙联合泼尼松用于转移性患者起始激素治疗：STAMPEDE随机试验（NCT00268476）的5年随访结果”的评论
Int J Cancer. 2022 Dec 15;151(12):2291-2292. doi: 10.1002/ijc.34246. Epub 2022 Sep 5.
2
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).醋酸阿比特龙联合泼尼松治疗开始激素治疗的转移性患者：来自 STAMPEDE 随机试验的 5 年随访结果（NCT00268476）。
Int J Cancer. 2022 Aug 1;151(3):422-434. doi: 10.1002/ijc.34018. Epub 2022 May 16.
3
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙联合泼尼松或联合恩扎卢胺治疗开始去势治疗的转移性前列腺癌患者：STAMPEDE 平台方案两项随机 3 期试验的最终结果。
Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.
4
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.新诊断转移性去势敏感性前列腺癌患者中阿比特龙联合泼尼松添加到雄激素剥夺治疗后的患者报告结局（LATITUDE）：一项国际性、随机 3 期临床试验。
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
5
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者后的雄激素信号靶向治疗的临床结局：COU-AA-302 的事后分析。
Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.
6
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.醋酸阿比特龙联合泼尼松治疗一线去势治疗失败的转移性去势抵抗性前列腺癌患者的疗效和安全性：一项单臂、4 期研究。
Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225.
7
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.阿帕鲁胺联合醋酸阿比特龙和泼尼松与安慰剂联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌（ACIS）：一项随机、安慰剂对照、双盲、多国、III 期研究。
Lancet Oncol. 2021 Nov;22(11):1541-1559. doi: 10.1016/S1470-2045(21)00402-2. Epub 2021 Sep 30.
8
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
9
STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.向雄激素生物合成抑制迈进以治疗高危激素初治前列腺癌：改变格局。
BJU Int. 2018 Jan;121(1):9-11. doi: 10.1111/bju.14050. Epub 2017 Oct 24.
10
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.在转移性激素敏感性前列腺癌男性患者中，在雄激素剥夺治疗基础上加用阿比特龙：一项系统评价和荟萃分析。
Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8.